The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

【拜耳在中国和美国同时递交非奈利酮心力衰竭适应症上市申请】1月11日，拜耳宣布同时向中国国家药品监督管理局药品审评中心（CDE）和美国食品药品监督管理局（FDA）递交非奈利酮（finerenone）心力衰竭（心衰）适应症上市申请，用于左心室射血分数（LVEF）≥40%的成年心衰患者，即左心室射血分数轻度降低（HFmrEF）或左心室射血分数保留（HFpEF）的心衰患者 ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

Bayer announced the submission of a marketing authorization application to the European Medicines Agency (EMA), seeking approval in the EU for the use of finerenone in adult patients with HF with a ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ...

Background: Chronic kidney disease (CKD) is a global public health issue. In recent years, the effectiveness of finerenone for treatment of CKD has been the subject of considerable debate. The main ...

The newest clinical guideline released by the ACC and American Heart Association (AHA), in collaboration with seven other societies, provides updated recommendations for perioperative cardiovascular ...

Get ready for the Great American Smokeout on Nov. 21. Click here to download this infographic from CardioSmart to support conversations with patients. In the U.S., smoking contributes to one-third of ...

The first month of the year reinforces what we already know to be true: TCTMD readers have diverse interests, spanning the breadth of cardiology research and practice. Our most-read article of January ...

Finerenone use in trial patients with HFpEF or HFmrEF increased hyperkalemia risk, especially in those with CKD. Finerenone use in patients with heart failure and preserved or mildly reduced ejection ...

Dr John Mandrola disagrees. Commentary, August 31, 2024 ESC 2024 Five Trials to Look For at ESC 2024 A sham trial of AF ablation, finerenone in heart failure, and transcatheter edge-to-edge repair ...